GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare for use of depemokimab in two indications. In China, the submitted indications are for an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 and older with type 2 inflammation characterised by blood eosinophil count, and add-on maintenance treatment of adult patients with inadequately controlled CRSwNP. In Japan, the submitted indications are for treatment of severe or refractory bronchial asthma and CRSwNP inadequately controlled with standard treatment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces EMA to review the regulatory application of Shingrix
- GSK, Oxford to establish GSK-Oxford Cancer Immuno-Prevention Programme
- GSK Pharma call volume above normal and directionally bullish
- GSK’s Jemperli Gains Expanded EU Approval for Endometrial Cancer
- GSK announces expanded EU approval in endometrial cancer for Jemperli combo